RUA: Revenue surged 92% year-over-year, but losses persist amid ongoing expansion and capital raising

About this update from Rua Bioscience Ltd.

Revenue nearly doubled year-over-year, driven by international expansion and new product launches, while net loss narrowed slightly. Liquidity improved through a successful rights offer and new borrowings, but material uncertainties remain regarding future profitability and going concern status.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Rua Bioscience Ltd.